<DOC>
	<DOCNO>NCT00042003</DOCNO>
	<brief_summary>To determine safety efficacy decitabine patient Philadelphia chromosome-positive chronic myelogenous leukemia blastic phase previously treat imatinib mesylate ( STI 571 ) become resistant/refractory find intolerant drug .</brief_summary>
	<brief_title>Phase II Trial Decitabine Patients With Chronic Myelogenous Leukemia Blast Phase Who Are Refractory Imatinib Mesylate ( Gleevec )</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Blast Crisis</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Imatinib Mesylate</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Inclusion : Histologically confirm diagnosis CML blast phase Ph chromosomepositive Previous treatment imatinib mesylate resulting : ) Hematologic Resistance / Hematologic Refractory : Based physician 's ( document ) decision discontinue imatinib mesylate treatment due failure continue benefit benefit patient , ii ) Imatinib Mesylate Intolerance : toxicity result physician 's ( document ) decision discontinue imatinib mesylate treatment . Patients must recover side effect previous CML therapy blast phase exception hydroxyurea Age &gt; /= 2 year Bilirubin &lt; /= 3 x upper limit normal ( ULN ) , SGOT SGPT &lt; /= 3 x ULN , except &lt; /= 5 x ULN leukemic involvement liver , serum creatinine &lt; /= 2 x ULN WHO performance status 03 A negative serum hCG pregnancy test patient childbearing potential Able give sign informed consent directly parent guardian minor Exclusion : Leukemic involvement central nervous system Active malignancy CML nonmelanoma cancer skin Previous treatment CML another investigational agent within 28 day study entry At study entry , patient treat : imatinib mesylate within past 48 hour , interferonalpha within past 48 hour ; homoharringtonine within past 14 day ; lowdose cytosine arabinoside within 7 day , moderate dose within 14 day , high dose within 28 day ; etoposide , anthracyclines , mitoxantrone within 21 day ; busulfan within past six week Patients receive hematopoietic stem cell transplantation within 6 week Day 1 decitabine therapy Patients Grade 3/4 cardiac disease serious concurrent medical condition . Patients pregnant nursing . All patient childbearing potential must practice effective method contraception study . Patients mental illness condition preclude ability give inform consent comply study requirement Patients systemic , uncontrolled infection</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2008</verification_date>
	<keyword>Chronic myelogenous leukemia</keyword>
	<keyword>CML</keyword>
	<keyword>CML-BP</keyword>
	<keyword>Blast phase</keyword>
	<keyword>Decitabine</keyword>
	<keyword>5-aza-2'deoxycytidine</keyword>
	<keyword>Methylation</keyword>
	<keyword>STI 571</keyword>
	<keyword>Imatinib mesylate</keyword>
	<keyword>Gleevec</keyword>
	<keyword>BCR/ABL</keyword>
</DOC>